[CAS NO. 2719679-31-7] MMT5-14
PRODUCTS SPECIFICATIONS [2719679-31-7]
DESCRIPTION [2719679-31-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 766.86 |
| Molecular Formula | C39H55N6O8P |
| SMILES | C[C@@H](C(OCCCCCCCC/C=C\C/C=C\CCCCC)=O)NP(OC1=CC=CC=C1)(OC[C@H]2O[C@@](C#N)(C3=CC=C4C(N)=NC=NN43)[C@H](O)[C@@H]2O)=O |
Summary
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC 50 s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19 [1] .
In Vitro
MMT5-14 (10 μM; 0-12 h) increases epithelial cell uptake
[1]
.
MMT5-14 (5 μM; 2 d) shows a better in vitro antiviral activity than remdesivir
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Vero-E6 cell line |
| Concentration: | 5 μM |
| Incubation Time: | 2 days |
| Result: | Inhibited SARS-CoV-2, alpha, beta, gamma and delta variants with EC 50 s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. |
In Vivo
MMT5-14 (10 mg/kg; i.v. once) shows a higher stability than remdesivir in microsomes, and shows higher concentrations of prodrugs and active metabolites (NTP) in blood and lungs [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Catheterized female hamsters [1] |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection; 10 mg/kg once |
| Result: | Showed higher intact prodrugs concentration than remdesivir in lungs after 4 hours injection, increased tissue exposure in most of the tissues and showed 5- to 10-fold higher tissue selectivity in lungs compared to remdesivir. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.